Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics

By |2021-05-17T18:52:31+01:00December 18th, 2019|News, Nityr|

Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases using Zydis ODT Technology

By |2022-01-28T15:52:20+00:00October 31st, 2019|News, Nityr|

NITYR (nitisinone) Tablets for tyrosinaemia type 1 will be available with fully subsidised access on the Life Saving Drugs Program across Australia

By |2021-05-17T18:52:31+01:00April 28th, 2019|News, Nityr|
Go to Top